Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NVUS Novus Therapeutics (NVUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Novus Therapeutics Stock (NASDAQ:NVUS) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Novus Therapeutics alerts:Sign Up Key Stats Today's Range$3.76▼$4.1750-Day Range$9.85▼$16.5052-Week Range$4.50▼$27.32Volume423,761 shsAverage Volume78,851 shsMarket Capitalization$5.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive NVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVUS Stock News HeadlinesPtc Therapeutics Share Price (PTCT.US)November 5, 2024 | lse.co.ukCAMP4 Therapeutics Corp.October 23, 2024 | money.usnews.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 21, 2024 | Weiss Ratings (Ad)Tango Therapeutics Share Price (TNGX.US)September 3, 2024 | lse.co.ukSarepta Therapeutics Share Price (SRPT.US)July 21, 2024 | lse.co.ukVivoryon Therapeutics NV VVYMarch 1, 2024 | morningstar.comViking Therapeutics IncFebruary 22, 2024 | money.usnews.comCYT Cyteir Therapeutics, Inc.December 28, 2023 | seekingalpha.comSee More Headlines NVUS Stock Analysis - Frequently Asked Questions How were Novus Therapeutics' earnings last quarter? Novus Therapeutics, Inc. (NASDAQ:NVUS) announced its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share for the quarter, missing analysts' consensus estimates of ($1.64) by $3.87. Read the conference call transcript. When did Novus Therapeutics' stock split? Novus Therapeutics shares reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings11/16/2020Today11/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVUS CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone949-238-8090FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-133.49% Return on Assets-30.52% Debt Debt-to-Equity RatioN/A Current Ratio18.78 Quick Ratio18.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.13 per share Price / Book0.29Miscellaneous Outstanding Shares1,436,000Free FloatN/AMarket Cap$5.53 million OptionableNot Optionable Beta2.07 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:NVUS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
